2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

3520 Iron addiction creates opposing vulnerabilities to iron starvation and ferroptosis in B-cell lymphoma

Etienne Leveille, MD, Leonardo de la Parra Soto2, Eden Bramson3, Ojas Chahal4, Mark E Robinson, PhD5, Song Wu, PhD6, Markus Müschen, MD-PhD7
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States

Background and significance: Iron has essential roles in diverse cellular functions, such as oxidative phosphorylation, DNA replication and repair, and epigenetic remodeling. However, excess labile iron promotes ferroptosis, a form of cell death characterized by iron-dependent peroxidation of lipid membranes. Cells must therefore carefully balance their need for iron metabolism with the inherent risk of ferroptosis it poses. We show that, while B-cell malignancies are addicted to iron metabolism, they are also particularly vulnerable to iron-mediated accumulation of reactive oxygen species and ferroptosis.

Results: Comparative analyses of publicly available CRISPR dependency and drug screening data (lymphoblasts.org), coupled with drug screens we have performed, identified that B-cell malignancies are significantly more dependent on TFRC (encoding the transferrin receptor) and vulnerable to iron chelators (ciclopirox, PAC-1, deferoxamine) than solid tumors. In line with these results, inducible deletion of TFRC in murine B-cell acute lymphoblastic leukemia and human B-cell lymphoma cell lines led to substantial cell death. To understand the mechanisms driving iron addiction in B-cell malignancies, we performed a whole-genome CRISPR knockout screen in a B-cell lymphoma cell line with deletion of TFRC or AAVS1 control and evaluated changes in gene dependency profiles across the two conditions. This analysis revealed that loss of the transferrin receptor and subsequent iron starvation alleviated cell dependence on the anti-ferroptotic defense GPX4, components of the B-cell receptor (BCR) signaling pathway (CD79A, CD79B, CD19) and one-carbon metabolism enzymes (DHFR, FPGS, MTHFD1, TYMS), connecting iron metabolism with key signaling and metabolic pathways in B-cell malignancies. Accordingly, B-cell receptor stimulation led to strong upregulation of surface TFRC in B-cell lymphoma. In addition, TFRC deletion led to resistance to methotrexate and the GPX4 inhibitor RSL3.

Conversely, our drug screens have shown that B-cell malignancies are more sensitive than solid tumors to FINO2, an iron oxidizer and ferroptosis inducer, suggesting high vulnerability to both iron starvation and oxidation in B-cell malignancies. CRISPR screens performed under the selective pressure of FINO2 in a B-cell acute lymphoblastic leukemia cell line suggest that mitochondrial iron handling plays a key role in mitigating iron oxidation-induced cell death, as identified by several synthetic lethal hits in this pathway (GLRX3, SLC25A28, SLC25A37). Similarly, multiple iron handling-related genes (PROM2, FPN1, FTH1, CD63) showed low RNA expression in B-cell malignancies compared to solid tumors, suggesting that the iron handling capacity of B-cell malignancies contributes to their vulnerability toward iron oxidation.

Given the vulnerability of B-cell malignancies to both iron starvation and oxidation, we aimed to combine those two approaches sequentially. We treated B-cell lymphoma cells with a brief course of the iron chelator deferoxamine, which rapidly triggered an iron starvation response, as evidenced by profound upregulation of surface expression of TFRC. Cells pre-treated with deferoxamine and undergoing an iron starvation response became substantially more vulnerable to sequential treatment with either FINO2 or the ferroptosis inducer RSL3. These findings suggest that iron addiction in B-cell malignancies can be utilized not only to eliminate cells by iron starvation, but also to leverage the iron starvation response, which increases sensitivity to ferroptosis.

Conclusions: Our findings identify iron homeostasis as a key vulnerability in B-cell malignancies and suggest that its bidirectional disruption through iron chelation or iron oxidation may represent a promising therapeutic strategy. In addition, our bidirectional CRISPR screens with TFRC deletion (iron starvation) and FINO2 (iron oxidation) revealed connections between key metabolic pathways (BCR signaling, one-carbon metabolism, mitochondrial iron handling) and vulnerability to disruption in iron metabolism in B-cell malignancies. These findings have the potential to be translated clinically given that multiple iron chelators are FDA-approved for iron overload and the ongoing development of multiple classes of ferroptosis-inducing drugs, with a potential for sequential treatment to enhance the efficacy of ferroptosis inducers.

Etienne Leveille, MD: No relevant conflicts of interest to declare.